Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRP-5051 extension in DMD
NCT03675126Phase 2Terminated
- Sponsor
- Sarepta Therapeutics
- Start
- Dec 2018
- Primary completion
- Aug 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Vesleteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Primary endpoint: Number of Participants Experiencing Treatment-emergent Adverse Events up to 135 weeks. Started Dec 2018; status: terminated.
02
Drugs
Vesleteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03675126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675126.